[Federal Register Volume 70, Number 86 (Thursday, May 5, 2005)]
[Notices]
[Page 23866]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-8986]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7908-2]


Intent To Grant a Co-Exclusive Patent License

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of intent to grant a co-exclusive license.

-----------------------------------------------------------------------

SUMMARY: Pursuant to 35 U.S.C. 207 (Patents) and 37 CFR part 404 (U.S. 
Government patent licensing regulations), EPA hereby gives notice of 
its intent to grant a co-exclusive, royalty-bearing, revocable license 
to practice the invention described and claimed in the U.S. patent 
application entitled Method for Isolating and Using Fungal Hemolysins, 
filed May 30, 2001, U.S. Serial Number 09/866,793, and all 
corresponding patents issued throughout the world, and all reexamined 
patents and reissued patents granted in connection with such patent 
application, to Roche Diagnostics Corporation, Indianapolis, Indiana, 
and to Aerotech Laboratories, Phoenix, Arizona.
    The invention was announced as being available for licensing in the 
May 12, 2003 issue of the Federal Register (68 FR 25371) as U.S. Patent 
Application Number 09/866,793, filed May 30, 2001, and claiming 
priority from a provisional application filed June 1, 2000.
    The proposed co-exclusive license will contain appropriate terms, 
limitations, and conditions to be negotiated in accordance with 35 
U.S.C. 209 and 37 CFR 404.5 and 404.7 of the U.S. Government patent 
licensing regulations.
    EPA will negotiate the final terms and conditions and grant the co-
exclusive license, unless within 15 days from the date of this notice 
EPA receives, at the address below, written objections to the grant, 
together with supporting documentation. The documentation from 
objecting parties having an interest in practicing the above patents 
should include an application for an exclusive or nonexclusive license 
with the information set forth in 37 CFR 404.8. The EPA Patent Attorney 
and other EPA officials will review all written responses and then make 
recommendations on a final decision to the Director or Deputy Director 
of the National Exposure Research Laboratory who have been delegated 
the authority to issue patent licenses under EPA Delegation 1-55.

DATES: Comments on this notice must be received by EPA at the address 
listed below by May 20, 2005.

FOR FURTHER INFORMATION CONTACT: Laura Scalise, Patent Attorney, Office 
of General Counsel (Mail Code 2377A), Environmental Protection Agency, 
Washington, DC 20460, telephone (202) 564-8303.

    Dated: April 27, 2005.
Marla E. Diamond,
Associate General Counsel, Finance and Operations Law Office.
[FR Doc. 05-8986 Filed 5-4-05; 8:45 am]
BILLING CODE 6560-50-P